Tonix Pharmaceuticals Holding Corp. · NASDAQ:TNXP
Tonix Pharmaceuticals — American Transplant Congress (ATC) 2023
13 slides from Tonix Pharmaceuticals's conference presentation, Jun 7, 2023
Slide 1: American Transplant Congress ATC 2023
AMERICAN TRANSPLANT CONGRESS ~ ATC2023 SAN DIEGO, CA -JUNE 3-7, 2023 SAN DIEGO CONVENTIO ‘ Stemeeting ora) feaczucasenpleca eed
Slide 2: Fc-Modified Anti-CD154 Mab Induced Long Term Renal Allograft Survival without Thromboembolic Complications
Fc - Modified Anti - CD154 Mab Induced Long Term Renal Allograft Survival without Thromboembolic Complications Ryo Otsuka, Grace Lassiter, Takayuki Hirose, Ahmad Karadagi , Toshihide Tomosugi , Ivy Rosales, Tatsuo Kawai Center for Transplantation Sciences Massachusetts General Hospital, Boston, MA,
Slide 3: Presenter disclosure
Ryo Otsuka, PhD Research Fellow Center for Transplantation Sciences, Massachusetts General Hospital, Boston, MA, USA I have no financial relationships with commercial interests to disclose. AND My presentation does not include discussion of off - label or investigational use.
Slide 4: Biology of CD154
Biology of CD154 ▪ CD154 is expressed on various types of cells, including activated T cells. ▪ Through interactions with its receptor, CD40, CD154 plays an important role in regulating interactions between T cells and antigen - presenting cells and thus affects several important functional events t
Slide 5: Investigational next generation anti-CD154 monoclonal antibody
*TNX - 1500 is an investigational new drug and has not been approved for any indication thereby lowering the potential for thrombosis. TNX - 1500: next generation anti - CD154 monoclonal antibody TNX - 1500 is engineered to target CD154 therapeutically while reducing Fc - receptor binding to overcom
Slide 6: Aims of the study
Aims of the study In this study, we compared TNX - 1500 with conventional anti - CD154 antibodies in terms of platelet activation in vitro and evaluated the efficacy of TNX - 1500 to prevent kidney allograft rejection in an NHP kidney transplantation model.
Slide 7: Assay for platelet activation
FSC (Log) SSC (Log) CD61 Platelets Leukocytes SSC (Log) 5C8=CD154 immune complex hu5C8=CD154 immune complex TNX - 1500=CD154 immune complex or 5C8 alone hu5C8 alone TNX - 1500 alone or or Assay for platelet activation Platelets NHP whole blood
Slide 8: Platelet activation after exposure to anti-CD154 immune complex
Activated platelets Platelet activation after exposure to anti - CD154 immune complex C D 6 2 P 5C8:sCD154 IC TNX:sCD154 IC PAC-1 Hu5C8:sCD154 IC FSC (Log) S S C ( L o g ) CD61 5C8 TNXHu5C8 PAC1 CD62P
Slide 9: Treatment regimens for NHP kidney transplantation
TNX monotherapy 20 mg/kg weekly TNX weekly TNX q2 weeks MMF daily 0 24126 184 108 1614 2220 TNX weekly TNX q2 weeks Rapamycin daily (trough 5-15 ng/ml) weeks Steroids Tacrolimus MMF No immunosuppression TNX - 1500 monotherapy (n=6) TNX - 1500 + MMF (n=6) TNX - 1500 + Rapamycin (n=3) Conventional imm
Slide 10: Kidney allograft survival
Kidney allograft survival No thrombosis - related complications were observed. Graft survival 83% 57% HE staining C4d staining Day 174 (TNX monotherapy)
Slide 11: Long-term observation beyond days
Long - term observation beyond 180 days Combination TNX admin. POD ID Mono MMF Q4 weeks >497 M10521 MMF Q4 weeks >665 M521 MMF Q4 weeks >422 M11321 MMF Q4 weeks >450 M8221 Rapa MMF Q4 weeks >350 M1922 180 240 300 360 420 480 0 2 4 6 8 10 Days Post-Transplant S e r u m C r e a t i n i n e ( m g /
Slide 12: Conclusion
Conclusion • TNX - 1500 can be an effective alternative to conventional immunosuppression therapy in kidney transplantation • TNX - 1500 inhibited renal allograft rejection without thromboembolism in NHPs • Optimal dosage for clinical application remains to be clarified • Fc - modification effective
Slide 13: Acknowledgment
Center for Transplantation Sciences Tatsuo Kawai Grace Lassiter Takayuki Hirose Ahmad Karadagi Toshihide Tomosugi Ashley D’Attilio Andrea Yanulevich Richard Pierson Kohei Kinoshita Abbas Dehnadi Cindy Miller Jane O Samantha Landino James Nawalaniec Dylan Muldoon Jayne Marie Muoio Knight Surgery Rese
Tonix Pharmaceuticals Holding — American Transplant Congress (ATC) 2023 on 6ix